{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 2 of 2 results
Status:
Possibly Marketed Outside US
Source:
MARQUIS
Source URL:
First approved in 2015
Source:
NADA141188
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Ponazuril, sold by the Bayer Corporation under the trade name Marquis, was the first FDA-approved treatment for equine protozoal myeloencephalitis (EPM) in horse, caused by Sarcocystis neurona. Also this drug was used in animals such as cats, dogs against coccidia, an intestinal parasite. Coccidia treatment is far shorter than treatment for EPM.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Toltrazuril (Baycox, Procox, Tolcox, Toltrazuril) is a veterinary drug approved in Europe for the treatment of parasitic infections caused by roundworms and coccidia. In dogs it is used in combination with emodepside (Procox).